so elanco the global omni channel leader. that is also another way to keep the resiliency in this market and continues to grow. >> do you have anything for feline immunodeficiency virus? they had a vaccine in this country, took it off the market in 2017. would be a very big market. any chance? >> yeah, i can't speak specifically to that. what i would say is there's a lot of research going on in autoimmune, a lot in the bio space. >> do you guys do it or everybody's doing it? >> it's a target for a few of us as companies. what i will say, jim, is right now at elanco, back to the priority, six major blockbusters. we got a first entry into the auto, you know, immune kind of market. excuse me, the durham market. >> zoetis has done a good job in durham. >> growing double digits. it only has a couple options. it's the number one reason pet owners take a dog to the vet is an itching dog. we're bringing an be alternative, a differentiated asset with a jack 1 inhibitor. next year we'll have a monoclonal antibody. this is a market that